Pharmaceutical Research Transparency Act of 2023

Cost and committee reports

Official records Congress.gov attaches to H.R. 3160.

• Constitutional authority statementThe sponsor’s statement of where the Constitution gives Congress the power to pass this bill. Statement by Mr. RASKIN, as printed in the Congressional Record (Vol. 169, No. 78, May 9, 2023, Page H2173):
  Article I, Section 8, clause 3. The single subject of this legislation is: Transparency of pharmaceutical research costs.
  Source: Congress.gov, Congressional Record May 9, 2023 ↗

  Evidence

  Field in the Congress.gov record

  constitutionalAuthorityStatementText

  Statement length

  121 characters

  Congress.gov bill record

  H.R. 3160, 118th Congress

  Congress.gov API record

  https://api.congress.gov/v3/bill/118/hr/3160

  Record last updated by Congress.gov

  December 5, 2025

  PORKER copy retrieved

  September 14, 2026

  Stored copy, SHA-256 of the file

  b8730c94c4c7e4daddcc43f61570ad1784546a5a3e9b1d34a3f5dfaad2eaee24

  PORKER shows the statement exactly as printed, with the page markup removed. It is the sponsor’s claim; it is not a legal finding.

Congress.gov’s record for this bill does not list a CBO cost estimate or a committee report (as of December 5, 2025). Not every bill gets one.

From the Congress.gov bill record for H.R. 3160, last updated December 5, 2025. PORKER’s copy was retrieved September 14, 2026 and is refreshed nightly. Open “Evidence” on any line for the record, field and file fingerprint.